Abstract
IL-5 is the most potent activator of eosinophils and is produced by Th2 cells and ILC2s. A role for IL-5 in eosinophil extracellular trap cell death, i.e., a proinflammatory cell death, has also been reported. Mepolizumab and benralizumab are humanized mAbs that target IL-5 and the IL-5 receptor α, respectively, and their therapeutic efficacy for severe asthma has been established. Although consistent differences in the efficacies of those drugs have not been proven, benralizumab extensively depleted eosinophils via Ab-dependent cell-mediated cytotoxicity. Blood eosinophil count, but not FeNO or IgE, is the best-established predictive biomarker of the efficacy of anti-IL-5 treatment. Regarding the choice of biologics, the balance between blood eosinophil count and FeNO, indication of comorbidities, longitudinal safety, and interval of injection should be considered. Mepolizumab was also effective in maintaining the remission of refractory eosinophilic granulomatous polyangiitis. Moreover, mepolizumab decreased the proportion of patients who required surgery and lowered the nasal polyp score in patients with chronic rhinosinusitis with nasal polyps; a further extensive trial is currently under way. In a phase II benralizumab stu...Continue Reading
Citations
Aug 21, 2020·International Journal of Immunopathology and Pharmacology·Nicola LombardoGirolamo Pelaia
Oct 12, 2020·Allergy·Koichiro AsanoMasami Taniguchi
Dec 10, 2020·Clinical and Molecular Allergy : CMA·Masato MurakiGerald J Gleich
Dec 20, 2020·Cancers·Stephanie AnnettTracy Robson
Jan 23, 2021·International Journal of Molecular Sciences·Kijeong LeeTae Hoon Kim
Feb 8, 2021·Respiratory Investigation·Ratoe SurayaYoshihiro Nishimura
Feb 17, 2021·Life Sciences·Xiang Ren, Zhenlin Wang
Jan 30, 2021·Immunology·Hemanth Kumar KandikattuAnil Mishra
Apr 4, 2020·Allergology International : Official Journal of the Japanese Society of Allergology·Kenji Izuhara
Feb 23, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Glenis K Scadding, Guy W Scadding
Jul 3, 2020·Respiratory Medicine Case Reports·Hiroki KagoshimaKazuhiko Shoji
Apr 13, 2021·American Journal of Rhinology & Allergy·Tetsuji TakabayashiShigeharu Fujieda
May 12, 2021·JCI Insight·Maya E KotasBenjamin Terrier
Jul 3, 2021·Nutrients·Ivan V BogdanovTatiana V Ovchinnikova
Mar 23, 2021·Arthritis & Rheumatology·Mineyo FukuchiMasami Taniguchi
Aug 14, 2021·Asia Pacific Allergy·Yui MiyabeShigeharu Ueki
Aug 14, 2021·Asia Pacific Allergy·Konomi KobayashiUNKNOWN iPOT-5 Investigators
Aug 25, 2021·International Immunology·Toshinori NakayamaShinichiro Motohashi